Information Provided By: 
Fly News Breaks for November 3, 2016
ACHN
Nov 3, 2016 | 11:57 EDT
Baird analyst Brian Skorney said the selloff in Achillion doesn't make sense saying the Factor D program was not in his estimates and has overpromised and underdelivered since day 1. Skorney said, with $3 in cash and a Johnson & Johnson (JNJ) deal with $5+ per share in milestones, he doesn't really care if Factor D is dead or not, and reiterates his Buy rating and $10 price target on Achillion shares.
News For ACHN From the Last 2 Days
There are no results for your query ACHN
